Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AIGIV · Anthrasil, NP-015

Plasma-derived product · Immune activation, directed at anthrax protective antigen (PA) · developed by Emergent BioSolutions Canada

Approved FDA, Mar 2015

EBS Developer

2 Registered trials

What is AIGIV?

AIGIV (Anthrasil) is an anthrax immune globulin intravenous preparation derived from human plasma containing anti-PA IgG antibodies. It is administered as a single intravenous infusion and is studied for treatment of inhalational anthrax.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Anthrasil, NP-015, ANTHRASIL
Drug type: Plasma-derived product
Targets: anthrax protective antigen (PA)
Mechanism: Immune activation, directed at anthrax protective antigen (PA)
Therapy area: Infectious disease
Developer: Emergent BioSolutions Canada Inc. (EBS)
FDA status: Approved as Anthrasil (March 24, 2015), BLA125562
UNII: VKZ83S945Z

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00845650	Phase 1/2	Anthrax	Completed	EBS
NCT03569553	N/A	Inhalational Anthrax	Not yet recruiting	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Inhalational AnthraxAnthrax

More from Emergent BioSolutions Canada

Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3 Botulinum Antitoxin Heptavalent Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind AIGIV

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z